Figure 3.

In vivo effect of cediranib on glioblastoma growth and angiogenesis. (A) Representative pictures (x16 magnification) of CAM assay in ovo and ex ovo at days 14 and 17. (B) Tumor growth was measured as described in Materials and Methods section. The results were expressed as mean percentage of tumor growth from day 14 (considered as 0%) to day 17 of development ± SD. (C) Counting of the blood vessels ex ovo at day 17. The results were expressed as the mean number of vessels for each group of treatments ± SD. Differences with P < .05 on the Student's t test were considered statistically significant (*). A total of 12 eggs were used for tumor formation (six were treated with cediranib and six with DMSO alone).